Nevertheless, the inhibition of IRE1α has already demonstrated positive therapeutic outcomes in Ewing′s sarcoma [168], MM [169], acute myeloid leukemia (AML) [170] as well as triple-negative breast cancer (TNBC) [165]. Here, ERN1 is linked to acute myeloid leukemia.